AGM
LFCR icon

Alpine Global Management’s Lifecore Biomedical LFCR Stock Holding History

Alpine Global Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,904
Closed -$107K – 311
2024
Q2 		$107K Buy
+20,904
New +$124K 0.02% 401
2021
Q4 		– Sell
-19,589
Closed -$181K – 795
2021
Q3 		$181K Buy
+19,589
New +$213K 0.04% 219

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpine Global Management's LFCR Position: Q3 2024 in Review

Alpine Global Management sold out of Lifecore Biomedical (LFCR) in Q3 2024, closing a stake of 20,904 shares — an estimated $107K sold.

Alpine Global Management first reported a position in LFCR in Q3 2021 and held it in 2 quarters. The position peaked at $181K in Q3 2021. 82 funds tracked by Wall St. Rank hold LFCR as of Q3 2024.

  • Alpine Global Management reported no remaining Lifecore Biomedical position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 20,904 Lifecore Biomedical shares in Q3 2024, an estimated $107K.
  • Alpine Global Management first reported a position in Lifecore Biomedical in Q3 2021 and held it in 2 quarters.
  • Alpine Global Management's Lifecore Biomedical position peaked at $181K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.